Notice of Special Interest (NOSI): Research Supplements to Promote Data Science Workforce Diversity to Reveal Scientific Insights of COVID-19 Testing Technologies (Admin Supp Clinical Trial Not Allowed)
Notice Number:

Key Dates

Release Date:

December 19, 2022

First Available Due Date:
February 13, 2023
Expiration Date:
February 20, 2023

Related Announcements

PA-21-071 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed)

RFA-OD-20-014 - RADx-Rad (U01 Clinical Trial Optional)

RFA-OD-21-008 - RADx-UP Phase II (U01 Clinical Trial Optional)

RFA-OD-21-009 - RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)

Issued by

Office of Data Science Strategy (ODSS)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Library of Medicine (NLM)


The purpose of this Notice of Special Interest (NOSI) is to enhance the diversityof the data science workforce to address questions and scientific inquiry related to SARS-CoV-2 through existing data resources in the Rapid Acceleration of Diagnostics Data Hub (RADx Data Hub), including and in conjunction with other data resources.


The Rapid Acceleration of Diagnostics (RADx) Initiative is driving some of the nation’s most creative biomedical innovation by rapidly developing multiple approaches to COVID-19 testing technologies to address national demands, with a focus on strategies for making testing broadly available. The RADx Data Hub is a centralized data repository for researchers to access datasets and analytic tools specific to the RADx program components: RADx-Tech and RADx Advanced Technology Platforms (RADx Tech/ATP), RADx Radical (RADx-rad), RADx Underserved Populations (RADx-UP), and Digital Health Solutions (DHS). The RADx-Tech aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect virus. The RADx-rad targets innovative settings or non-traditional technologies to evaluate the usability, accessibility, robustness, or accuracy of the detection of COVID-19 infections. The RADx-UP aims to examine infection patterns and efforts for increasing access to and effectiveness of testing methods through engagement with diverse communities and populations. The DHS aims to facilitate approaches that leverage multiple data sources, privacy-preserving technologies, and computational tools for managing population health and individuals’ lives during the COVID-19 pandemic.

Research Objective

The research objective of this NOSI is to stimulate  development of data science approaches for the RADx programs to catalyze the scientific value and reveal scientific insights.  This NOSI aims to support Administrative Supplements to the exisiting RADx parent awards to promote the data science workforce in biomedical research.

This Supplement may be used to support a variety of topic areas, examples of topic areas include, but are not limited to:

  • Validatepublic health measures
  • Inform patient care
  • Reduce health disparities for underserved and vulnerable populations
  • Drive innovation in technologies offering more user-friendly designs
  • Help stop and/or track the spread of COVID-19 virus or co-infectious materials
  • Address better strategies to timely equip the biomedical workforce to test and identify future pathogens and other diseases

Award Budget

Application budget needs to reflect the actual needs of the proposed project. One-time supplement budget requests may not exceed $150,000 direct costs. The administrative supplement budget request is limited to 1 year. Budgets may not exceed the total direct costs of the current parent award. The number of awards is contingent upon availability of National Institutes of Health (NIH) Office of Data Science Strategy (ODSS) funds and the submission of meritorious applications.

Award Project Period

To be eligible, the existing parent award must be able to receive funds in FY2023 (October 1, 2022 to September 30, 2023), and not be in a no-cost extension period at the time of the parent award. The Supplement may not extend beyond the project period of the existing parent award


This announcement is for supplements to existing RADx parent projects. A broad range of projects that have significant data science components are eligible. Proposed projects must be within the scope of the parent awards. Only one independent research project request per PD/PI will be considered.

Applications that are not appropriate and out of scope for this NOSI include:

  • Applications that are out of scope of the parent awards
  • Applications that do not explicitly meet all the requirements stated elsewhere in this NOSI.
  • Applications that do not provide data science mentorship and expertise to increase workforce development.

Administrative Review Process

Administrative Supplements do not receive peer review. Each NIH Institute, Center, or Office (ICO) will conduct administrative reviews of applications submitted to their ICO separately. Submitted applications must follow the guidelines of the ICO that funds the parent grants. The ICOs of the parent grants will assess for responsivensss and itentify the most meritorious applications submitted for funding consideration. The NIH/ODSS will determine and support the most meritorious applications based upon availability of funds.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-21-071 Reserach Supplement to Promote Diversity in Health-related Research (Admin supp - Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and PA-21-071 must be followed, with the following additions:

  • Application Due Date – February 20, 2023 by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include “NOT-OD-23-041” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one year of support only.
  • The Research Strategy section of the application is limited to 6 pages.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this NOSI to facilitate efficient processing of the request.

Applications nonresponsive to terms of this NOSI will not be considered.


Please direct all inquiries to:

Scientific/Research Contacts

Partha Bhattacharyya, Ph.D.
National Institute on Aging (NIA)
Phone: (301) 496-3131

Rebecca F. Rosen, Ph.D.
Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD)

Anissa F Brown, Ph.D.
National Institute of Dental & Craniofacial Research (NIDCR)

Susan Nicole Wright, Ph.D.
National Institute on Drug Abuse (NIDA)
Phone: 301-402-6683

Lori A.J. Scott-Sheldon, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-792-2309

Sung Sug (Sarah) Yoon, RN, PhD
National Institute of Nursing Research (NINR)
Telephone: 301-402-6959

Nancy L. Jones, Ph.D.
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-594-8945

Yanli Wang, Ph.D.
National Library of Medicine (NLM)
Phone: 301-827-7092

Lucy Hsu, M.P.H.
Office of Data Science Strategy (ODSS)